May 9 |
MEI Pharma GAAP EPS of -$1.37 beats by $0.12
|
May 9 |
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
|
Apr 11 |
MEI Pharma shelves plans for a second return of capital
|
Apr 11 |
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
|
Apr 11 |
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (AvastinĀ®) in Relapsed Metastatic Colorectal Cancer Patients
|
Apr 10 |
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
|
Mar 26 |
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
|
Mar 9 |
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
|
Feb 20 |
MEI Pharma files for $100M mixed shelf
|
Feb 13 |
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
|